The outcome of Ph-negative acute lymphoblastic leukemia presenting during pregnancy and treated on the Russian prospective multicenter trial RALL-2009. (May 2021)

• Record Type: Journal Article
• Authors: Parovichnikova, Elena N.; Troitskaya, Vera V.; Gavrilina, Olga A.; Sokolov, Andrey N.; Kokhno, Alina V.; Klyasova, Galina A.; Kuzmina, Larisa A.; Galstyan, Gennadiy M.; Makhinya, Sergey A.; Latyshkevich, Oleg A.; Kaporskaya, Tatyana S.; Lapin, Valery A.; Chabaeva, Yulia A.; Kulikov, Sergey M.; Savchenko, Valery G.
• Is Part Of: Leukemia research. Volume 104(2021)
• Publication Date: 2021-05
• Subjects: Ph-negative ALL in adults -- Pregnancy -- Clinical trial; Leukemia -- Periodicals; Leukemia -- Periodicals; Leucémie -- Périodiques; Leukemia; Periodicals; Electronic journals; Electronic journals; 616.9941905
• DOI: 10.1016/j.leukres.2021.106536
• Languages: English
• ISSNs: 0145-2126

Abstract

Highlights: Pregnant women diagnosed with ALL can be included in clinical trials. There are some specific features of ALL diagnosed during pregnancy. Pregnancy does not influence the long term outcome in ALL. All children exposed to maternal chemotherapy are now alive and well. Abstract: We report the data on 15 women who presented with Ph-negative acute lymphoblastic leukemia (ALL) between Jan 2009 until Dec 2016 and who were treated on the prospective multicenter RALL-2009 clinical trial. A comparison of their outcome was made with 129 non-pregnant females who entered the study and were treated by the same schedule. 10-years OS for pregnant and non-pregnant women was 58.6 % (29.6 %–85.0 %) and 43.3 % (32.1 %–58.8 %), DFS was 46 % (15.2 %–78.8 %) and 51 % (39.7 %–64.6 %); probability of relapse was 49 % (16.6 %–83.3 %) and 40.3 % (27.3 %–53.4 %), respectively. Twelve born during the study children are well and alive with a median age 5 years 2 months (2 years – 9 years). Though small, our study has shown some specific features of ALL diagnosed during pregnancy (more T-cell ALL, higher initial WBC, later responses) and has shown that the long-term outcome of women with ALL treated while pregnant is equivalent to female control patients treated on the same protocol.